Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
The early response was not positive, with shares down 2.6% to US$39.89 in the past week. The results don't look great, especially considering that statutory losses grew 17% toUS$0.68 per share. Revenues of US$160,205,000 did beat expectations by 9.7%, but it looks like a bit of a cold comfort. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. View our latest analysis for Legend Biotech Following the latest results, Legend Biotech's 20 analysts are now forecasting revenues of US$1.04b in 2025. This would be a huge 100% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 55% to US$0.85. Before this latest report, the consensus had
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy DevelopmentPR Newswire
- Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.MarketBeat
- Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Highlights: CARVYKTI's Impressive Growth Amid ... [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating OfficerBusiness Wire
LEGN
Earnings
- 5/13/24 - Beat
LEGN
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- 11/12/24 - Form SC
- LEGN's page on the SEC website